The preparation and characterization of anti-VEGFR2 conjugated, paclitaxel-loaded PLLA or PLGA microspheres for the systemic targeting of human prostate tumors

Cancer Chemotherapy and Pharmacology

Volumn 61, Issue 6, 2008, Pages 997-1005

  Lu, Jianjun ^a   Jackson, John K ^a   Gleave, Martin E ^a   Burt, Helen M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Anti VEGFR; Microspheres; Paclitaxel; Prostate cancer

Indexed keywords

CYANOGEN BROMIDE; MICROSPHERE; PACLITAXEL; POLYGLACTIN; POLYLACTIC ACID; POLYVINYL ALCOHOL; VASCULOTROPIN ANTIBODY;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DETECTION; ARTICLE; CANCER INHIBITION; CANCER LOCALIZATION; CONJUGATION; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DISPERSION; DRUG CONJUGATION; DRUG EFFICACY; DRUG TARGETING; EVAPORATION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; SINGLE DRUG DOSE; SOLVENT EFFECT;

ANIMALS; ANTIBODIES, BLOCKING; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; ENDOTHELIAL CELLS; FLUORESCEIN-5-ISOTHIOCYANATE; HUMANS; IMMUNOGLOBULIN G; LACTIC ACID; MALE; MICE; MICE, INBRED BALB C; MICROSPHERES; NEOPLASM TRANSPLANTATION; PACLITAXEL; PARTICLE SIZE; PILOT PROJECTS; POLYGLYCOLIC ACID; POLYMERS; PROSTATIC NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 41049089702     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-007-0557-x     Document Type: Article

References (35)

1. Arshady R, Monshipouri M (eds) (1999) Targeted delivery of microparticulate carriers. Microspheres, microcapsules, and liposomes: medical and biotechnology applications, vol 2. Imperial College, University of London, Citus Books, London
2. Balbay MD, Pettaway CA, Kuniyasu H, Inouse K, Ramirez E, Li E, Fidler IJ, Dinney CP (1999) Highly metastatic human prostate cancer growing within the prostate of athymic mice overexpresses vascular endothelial growth factor. Clin Cancer Res 5(4):783-789
3. Berkland C, Kyekyoon K, Pack DW (2001) Fabrication of PLG microspheres with precisely controlled and monodisperse size distributions. J Control Release 73:59-74
4. Bitz C, Doelker E (1996) Influence of the preparation method on residual solvents in biodegradable microspheres. Int J Pharm 131:171-181
5. Brekken RA, Thorpe PE (2001) VEGF-VEGF receptor complexes as markers of tumor vascular endothelium. J Control Release 74:173-181
6. Dhanaraj SA, Santhi K, Pandit V, Raghu R, Vijayan P, Vasudevan M, Suresh B (2005) Study on the active delivery of methotrexate microspheres with mouse monoclonal IgG in tumour-induced mice. Indian J Pharm Sci 67:540-543
7. Dordunoo SK, Jackson JK, Arsenault LA, Oktaba AMC, Hunter WC, Burt HM (1995) Taxol encapsulation in poly(caprolactone) microspheres. Cancer Chemother Pharmacol 36:279-282
8. Ferrara N, Hillan KJ, Novotny W (2005) Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 333:328-335
9. Fonseca C, Simoes S, Gaspar R (2002) Paclitaxel loaded PLGA nanoparticles: preparation, physiochemical characterization and in vitro anti-tumoral activity. J Control Release 83:273-286
10. Freitas S, Merkle HP, Gander B (2005) Microencapsulation by solvent extraction/evaporation: reviewing the state of the art of microsphere preparation process technology. J Control Release 102:313-332
11. Gille H, Kowalski J, Li B, LeCouter J, Moffat B, Zioncheck TF, Pelletier N, Ferrara N (2001) Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants. J Biol Chem 276(5):3222-3230
12. Gupte A, Ciftci K (2004) Formulation and characterization of Paclitaxel, 5-FU and Paclitaxel + 5-FU microspheres. Int J Pharm 276:93-106
13. Hermanson GT, Mallia K, Smith PK (eds) (1992) Immobilized affinity ligand techniques. Academic, New York
14. Hou JM, Liu JY, Yang L, Zhao X, Tian L, Ding ZY, Wen YJ, Niu T, Xiao F, Lou YY, Tan GH, Deng HX, Li J, Yang JL, Mao YQ, Kan B, Wu Y, Li Q, Wei YQ (2005) Combination of low dose gemcitabine and recombinant quail vascular endothelial growth factor receptor-2 as a vaccine induces synergistic antitumor activities. Oncology 69(1):81-87
15. Huang YQ, Li JJ, Hu L, Lee M, Karpatkin S (2001) Thrombin induces increased expression and secretion of VEGF from human FS4 fibroblasts, DU145 prostate cells and CHRF megakaryocytes. Thromb Haemost 86(4):1094-1098
16. Jackson JK, Gleave JE, Yago V, Beraldi E, Hunter WL, Burt HM (2000) The suppression of human prostate tumor growth in mice by the intra-tumoral injection of a slow release polymeric paste formulation of paclitaxel. Cancer Res 60:4146-4151
17. Jackson JK, Springate CMK, Hunter WL, Burt HM (2000) Neutrophil activation by plasma opsonized polymeric microspheres: inhibitory effect of Pluronic F127. Biomaterials 21:1483-1491
18. Keegan ME, Royce SM, Fahmy T, Saltzman WM (2006) In vitro evaluation of biodegradable microspheres with surface-bound ligands. J Control Release 110:574-580
19. Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, Bohlen P, Kerbel RS (2000) Continuous low dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 105(8):R15-R24
20. Kollerman J, Helpap B (2001) Expression of vascular endothelial growth factor (VEGF) and VEGF receptor Flk-1 in benign, premalignant, and malignant prostate tissue. Am J Clin Pathol 116(1):115-121
21. Liggins RT, Burt HM (2001) Paclitaxel loaded poly(l-lactic acid) microspheres: properties of microspheres made with low molecular weight polymers. Int J Pharm 222:19-33
22. Liggins RT, D'Amours S, Demetrick JS, Machan LS, Burt HM (2000) Paclitaxel loaded poly(l-lactic acid) microspheres for the prevention of intraperitoneal carcinomatosis after a surgical repair and tumor cell spill. Biomaterials 21:1959-1969
23. Liggins RT, Cruz T, Min W, Liang L, Hunter WL, Burt HM (2004) Intra-articular treatment of arthritis with microsphere formulations of paclitaxel: biocompatibility and efficacy determinations in rabbits. Inflamm Res 53:363-372
24. Ma L, Francia G, Viloria-Petit A, Hicklin DJ, du Manoir J, Rak J, Kerbel RS (2005) In vitro procoagulant activity induced in endothelial cells by chemotherapy and antiangiogenic drug combinations: modulation by lower-dose chemotherapy. Cancer Res 65(12):5365-5373
25. Maruyama K (2000) In vivo targeting of liposomes. Biol Pharm Bull 23(7):791-799
26. Molema G, Meijer DK, de Leij LF (1998) Tumor vasculature targeted therapies: getting the players organized. Biochem Pharmacol 55(12):1939-1945
27. Muramatsu N, Kondo T (1995) An approach to prepare microparticles of uniform size. J Microencapsul 12(2):129-136
28. Onetto N, Canetta R, Winograd R (1993) Overview of taxol safety. J Natl Cancer Inst Monogr 15:131-139
29. Ramaswamy M, Zhang X, Burt HM, Wasan (1997) The human plasma distribution of free paclitaxel and paclitaxel associated with diblock copolymers. J Pharm Sci 86:460-464
30. Scholes PD, Coombes L, Illum L, Davis SS, Watts JF, Ustariz C, Vert M, Davies MC (1999) Detection and determination of surface levels of poloxamer and PVA surfactant on biodegradable microspheres using SSIMS and XPS. J Control Release 59:261-278
31. Sharma A, Straubinger RM (1994) Novel taxol formulations: preparation and characterization of taxol-containing liposomes. Pharm Res 11:889-896
32. Springate CM, Jackson JK, Gleave ME, Burt HM (2005) Efficacy of an intra-tumoral controlled release formulation of clusterin antisense oligonucleotide complexed with chitosan containing paclitaxel or docetaxel in prostate cancer xenograft models. Cancer Chemother Pharmacol 56(3):239-247
33. Torchilin VP, Lukyanov AN, Gao Z, Papahadjopoulos-Sternberg B (2003) Immunomicelles: targeted pharmaceutical carriers for poorly soluble drugs. Proc Natl Acad Sci USA 100(10):6039-6044
34. Witte L, Hicklin DJ, Zhu Z, Pytowski B, Kotanides H, Rockwell P, Bohlen P (1998) Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy. Cancer Metastasis Rev 17:155-161
35. Zhifang Z, Mingxing Z, Shenghao W, Fang L, Wenzhao S (1993) Preparation and evaluation in vitro and vivo of copoly (lactic/glycolic) acid microspheres containing norethisterone. Biomater Artif Cells Immobilization Biotechnol 21(1):71-84